Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

MoonLake Immunotherapeutics Stock Plummets After Phase 3 Data Readouts

Market, Down, Creative,Crash,Recession,Chart,With,Falling,Red,Arrow.,Business,And

MoonLake Immunotherapeutics‘ (NASDAQ: MLTX) stock price fell off a cliff Monday after it reported week-16 results from its Phase 3 VELA-1 and VELA-2 trials.

The trials used HiSCR75—a 75% reduction in abscess and inflammatory nodule count with no increase in abscesses or draining tunnels—as the primary endpoint.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.